Este estándar internacionalmente reconocido establece las mejores prácticas para gestionar riesgos relacionados con la seguridad de los datos, implementar controles efectivos y garantizar la protección de la información sensible.
Esta nueva certificación reafirma el compromiso de Atrys con la excelencia en la gestión de la seguridad de la información, complementando las certificaciones ya existentes en sus divisiones de oncología y prevención
Atrys Health (ATRY), compañía healthtech global que presta servicios de prevención, diagnóstico y tratamiento médico de precisión, líder en telemedicina y tratamiento oncológico, anuncia que su división de diagnóstico ha obtenido la certificación ISO 27001 en tres de sus unidades de negocio de telediagnóstico – Chile, Colombia y España – y en su actividad de Anatomía Patológica. Este importante avance en seguridad de la información se une a las certificaciones ya obtenidas anteriormente por el Grupo Atrys en Oncología y Prevención (ASPY), esta última también certificada por el Esquema Nacional de Seguridad (ENS).
La certificación ISO 27001 define los requisitos para un Sistema de Gestión de Seguridad de la Información (SGSI) eficaz. Este estándar internacionalmente reconocido establece las mejores prácticas para gestionar riesgos relacionados con la seguridad de los datos, implementar controles efectivos y garantizar la protección de la información sensible. Su obtención reafirma el compromiso de Atrys con la seguridad de la información y aporta numerosos beneficios a la organización. Entre ellos, una mayor protección de la confidencialidad, integridad y disponibilidad de la información de sus clientes y pacientes; el refuerzo de la confianza depositada de sus socios, colaboradores y clientes, y una garantía de la mejora continua de sus procesos de seguridad.
Para Atrys, este éxito es fruto del trabajo en equipo y el compromiso de diversas áreas y departamentos que participaron activamente en el exigente proceso requerido para la certificación.
Según Luis Durán, CTO global de Atrys, “Este logro no sólo refuerza el posicionamiento de Atrys como empresa de referencia en el sector, sino su capacidad para adoptar y cumplir con los más altos estándares internacionales en seguridad de la información. Durante los próximos meses, seguiremos trabajando para conseguir esta certificación en todos los negocios de la compañía”
The BLinfoPred initiative seeks to develop and validate predictive tools based on omics technology and liquid biopsy that enable accurate genetic classification of diffuse large B-cell lymphoma (DLBCL) and prediction of therapeutic response
BLinfoPred, the result of a consortium between Atrys and the Instituto de Investigación Sanitaria Puerta de Hierro – Segovia de Arana, has received funding from the State Research Agency, which reflects the value of public-private collaboration to continue advancing in cancer research
Atrys Health, a global healthtech company that provides prevention, diagnosis and precision medical treatment services, leader in telemedicine and oncology treatment, will lead the BLinfoPred project, focused on the development of advanced technologies to improve the diagnosis and treatment of Lymphoma B Diffuse Large Cell Lymphoma (LBDCG), an aggressive type of lymphoma.
BLinfoPred is an initiative resulting from a consortium between our company and the Lymphoma Research Group of the Instituto de Investigación Sanitaria Puerta de Hierro – Segovia de Arana (IDIPHISA), attached to the Medical Oncology Department of the Hospital Universitario Puerta de Hierro Majadahonda. This consortium has just received financial support in the call for grants for public-private collaboration projects of the State Plan for Scientific, Technical and Innovation Research 2021-2023.
LBDCG is a complex and aggressive lymphoma that responds favorably to standard treatment with immunochemotherapy (R-CHOP) in approximately 70% of cases. However, in the remaining patients it shows resistance or relapses, which complicates its clinical management. Currently, there are no reliable tools to accurately predict the response to treatment. Therefore, through BLinfoPred, Atrys and the Lymphoma Research Group of the Instituto de Investigación Sanitaria Puerta de Hierro – Segovia de Arana, seek to develop and validate predictive tools based on omics technology and liquid biopsy, which allow an accurate genetic classification of LBDCG and the prediction of therapeutic response.
As Dr. Margarita Sánchez-Beato, head of IDIPHISA’s Lymphoma Research Group, points out, “the BLinfoPred project represents a key advance in the personalization of the treatment of Diffuse Large Cell Lymphoma B. Through the creation of a new cohorts, the BLinfoPred project will be able to identify and validate the most appropriate treatment for LBDCG. Through the creation of a cohort of patients and genomic characterization by liquid biopsy, we seek to accurately classify lymphoma and predict response to treatment. In addition, the development of artificial intelligence models and a validated clinical kit will allow us to identify patients at higher risk and improve their clinical management, offering access to personalized treatments,” he said.
For his part, Dr. José Antonio López, medical director of the Precision Medicine area at Atrys, emphasizes that the development of this type of project is necessary to contribute to improving the treatment of Diffuse Large Cell Lymphoma B and to broaden access to advanced predictive tools in personalized oncology. “These advances make it possible to develop more precise and effective therapies for patients, adapted to the molecular characteristics of their disease,” he said.
In addition to the participation of Atrys and IDIPHISA’s Lymphoma Research Group, the BLinfoPred consortium has the support of the Oncology Group for the Treatment and Study of Lymphomas (GOTEL), which collaborates in the recruitment of patients and the collection of clinical data and biological samples.
Atrys Health reinforces its position as a leader in telemedicine and precision diagnostic services, using advanced technology to transform medical care in Chile.
The pilot program at the Félix Bulnes Hospital has achieved an 88% reduction in patient care times and an 80% reduction in patient service costs.
With 6.8 million online diagnoses performed per year and a global team of 850 specialists, Atrys continues to position itself as a reference in the field of telediagnosis in Spanish.
Atrys Health (ATRY), a global healthtech company that provides prevention, diagnosis and precision medical treatment services and is a pioneer in telemedicine and oncology treatment, has presented the results of an ambitious pilot program to reduce waiting lists at the Félix Bulnes Hospital, part of the Western Metropolitan Health Service in Santiago. This project, which began seven months ago, has managed to attend 8,000 patients in the specialties of cardiology, internal medicine, neurology and dermatology, achieving an 88% reduction in waiting times and an 80% reduction in patient service costs.
This program, based on the use of telemedicine and artificial intelligence services, makes it possible to review medical examinations and refer the results of those that are altered to a professional, thus making the doctor’s time much more efficient by allowing him to concentrate his efforts on those who have a pathology.
The success of the program has led the hospital to entrust Atrys with the care of another 20,000 new patients. In addition, this model is being taken to 8 other hospitals in the Reloncaví Health Service, one of the 29 territorial services of Chile’s National Health Services System.
In addition, Atrys and the Ministry of Health will continue to collaborate in the development of new projects to improve public healthcare in the country.
The Country Manager of Atrys in Chile, Juan Mella, wanted to highlight “The excellent results achieved at the Félix Bulnes Hospital demonstrate the potential of technology to transform public health, reducing costs and care times. We are proud to continue collaborating with the Chilean healthcare system to improve the quality of life of thousands of patients”.
Local impact driven by a global perspective
Atrys leverages its experience developed in Spain, where it has led hybrid medical services that combine face-to-face care and telemedicine, efficiently serving millions of patients. The company currently has a team of 850 specialists worldwide and an operating model that performs more than 7 million online diagnoses per year, consolidating its position as a leader in the field of telediagnosis in Spanish.
Atrys reaffirms its commitment to innovate and work hand in hand with public health systems to offer effective solutions that respond to the needs of the population in Chile and other parts of the world.
González Sans has more than 30 years of experience in management and business development in different sectors.
Atrys, leader in advanced medicine, reaffirms its commitment to preventive health as a key area of its activity.
Atrys, a global healthtech company that provides prevention, diagnosis and precision medical treatment services, leader in telemedicine and oncology treatment, continues to grow and boost its areas of expertise. With the commitment to strengthen its prevention services, Atrys has just announced the appointment of Rosa González Sans as the new managing director of this area. González Sans, who joined the company in April of this year as director of Optimization and Improvement, will now also assume leadership in the development and expansion of the company’s prevention projects, ensuring their growth, sustainability and meeting the objectives that help strengthen Atrys’ position as a leading healthcare services company.
With more than 30 years of experience, Rosa González Sans brings a multidisciplinary profile and leadership in various sectors. Founder and director of Mediaworks, S.A., in 2008 she joined Audax Energía holding positions of responsibility in Finance and Administration; she later became CFO and Business Development Manager in the Italian subsidiary, leading its expansion, and of which she is currently still a director.
In 2019, González Sans participated in the merger process between Audax Energía and Fersa Energía Renovables, which gave rise to Audax Renovables (AR), and of which, since 2021, she has been a member of its Board of Directors.
In 2022, she took over the corporate management of the holding company Excelsior Times S.L., which manages more than 70 companies, and was appointed to the Board of Directors of La Sirena Alimentación Congelada, Agro Water Almonds and Awa Segre, among others. Since 2023, she has also been a trustee of the Fundació Capital Europea del Bàsquet.
In 2021 she was appointed proprietary director of Atrys Health, representing Excelsior Times S.L., until June 2024, when she joins the management team of Atrys.
According to Isabel Lozano, CEO of Atrys, “Rosa’s appointment strengthens the company’s management team, and will contribute to enhance the excellent capabilities of this important division of our group, driving synergies with the diagnostics and oncology divisions. I am confident that her previous experience in high-growth sectors will bring a new vision to further strengthen Atrys’ mission of putting preventive health at the center of our priorities.”
The new managing director, Rosa González Sans, emphasized that “It is an honor to assume the leadership of the Prevention area at Atrys and contribute to the development of one of the most decisive areas for people’s wellbeing. In a world in which prevention is key to improving quality of life and reducing the incidence of disease, my goal is to position prevention as a strategic axis, promoting synergies with the areas of Oncology and Diagnostics to develop innovative solutions that promote health at all levels, from occupational prevention to personalized treatment for our patients”.
The company’s revenues to September 2024 exceeded 155.6 million euros, confirming growth of 7.2% at constant exchange rates in the first nine months of the year.
Adjusted EBITDA increased by 31.7% to 31.2 million euros.
The company strengthened its leadership in LATAM, the region with the strongest growth in the first nine months, with a 10.6% increase in revenues, which rose to 18.6% at constant exchange rates.
Operating cash flow increased 60.8% year-on-year to 18.3 million euros by September 2024.
Atrys, a global healthtech company providing precision medical prevention, diagnosis and treatment services and a leader in telemedicine and oncology treatment, today announced results for the third quarter of 2024, reflecting solid overall growth in both revenue and Adjusted EBITDA.
In the first nine months of 2024, the company’s revenues increased 5.8% year-on-year, or 7.2% at constant exchange rates, to 155.6 million euro. This increase was driven by the generalised growth of all the company’s business lines, with special emphasis on the Oncology area.
Gross margin grew 4.2% year-on-year to September to 102.6 million euro, compared to 98.5 million euro in the first nine months of 2023. The gross margin over revenues was 66%, slightly lower than in the same period last year, due to the greater weight of the Medical Oncology and Diagnostics areas in the company’s overall revenues.
EBITDA exceeded EUR 26.2 million, an increase of 33.1% over the previous year, and Adjusted EBITDA improved to EUR 31.2 million in the first nine months of the year, 31.7% higher than in the same period of 2023. In addition, the Adjusted EBITDA margin over revenues improved substantially from 16.09% to 20.02%, supported by the operational growth and cost savings and efficiency plans implemented in the first nine months of 2024.
For its part, the company has contained CAPEX investment, which stood at €7.97 million, down 4.6% due to lower CAPEX growth. In addition, operating cash flow has increased by 60.8% compared to the previous year, reaching €18.3 million as of September 2024.
Growth in all business lines with a focus on Latin America
The company’s results for the first nine months of 2024 confirm the positive evolution of all its business areas, with special emphasis in the Oncology segment. Added to this is the Group’s firm commitment to the Latin American countries in which it is present, specifically Brazil, Chile, Colombia, Mexico and Peru, where Atrys has increased its revenues by 10.6%, or 18.6% considering a constant exchange rate, to reach 30.6 million euros at the end of September 2024.
By business segment, revenues in the Diagnostics area amounted to EUR 48.6 million, with a 5% growth in revenues (9.5% at constant exchange rates). Of note was the good performance of the laboratories segment, which grew 30.9%, driven by the new laboratory in Madrid.
The Oncology segment, on the other hand, grew 7.6% to 45.6 million euros. Of note in this segment was the 11.6% increase in the Medical Oncology area, driven by increased activity in Mexico.
The Prevention area increased its turnover by 5.1% to 61.4 million euros in the first nine months of the year. This growth was driven by a 4% increase in the number of medical check-ups and a 2% increase in the average ticket per check-up.
These awards, granted within the framework of the UB-Atrys Chair, recognize excellence and innovation in research and promote the dissemination of knowledge in the field of radiation oncology, a medical specialty that is fundamental to progress in the treatment of cancer.
The third edition of the awards recognizes three articles that respectively address solutions to mitigate side effects derived from stereotactic radiosurgery, to detect predictive biomarkers of chemotherapy resistance to optimize treatment effectiveness and the use of artificial intelligence to predict radiation toxicities.
The awards ceremony, held at the XXII SEOR 2024 National Congress, was attended by Dr. Jean Bourhis, CEO of GORTEC, Professor of Radiation Oncology at the University Hospital Center of Lausanne in Switzerland and former President of the European Society for Radiotherapy and Oncology, among other specialists in radiation oncology.
Madrid, September 26, 2024. Atrys, a global healthtech company that provides services for prevention, diagnosis and precision medical treatment and pioneer in telemedicine and next-generation radiotherapy, and the University of Barcelona (UB), recognize innovation in the field of Radiation Oncology in the III edition of the ‘Research Awards in Personalized Radiotherapy’. This recognition, linked to the UB Atrys Chair, is awarded since 2021 to the three research articles published in internationally prestigious journals that stand out for their excellence and for their differential and innovative proposal to advance in the different therapies to combat cancer, with the aim of promoting research in the field of radiation oncology, and more specifically, in the field of translational radiotherapy.
The presentation of the awards took place within the framework of the XXII SEOR 2024 National Congress, held between September 25 and 27 in Oviedo. During the inaugural conference, Dr. Ferrán Guedea, head of Radiation Oncology at the Catalan Institute of Oncology (ICO) and director of the UB Atrys Chair, Dr. Jean Bourhis, professor at the University Hospital Center of Lausanne and former president of the European Society for Radiotherapy and Oncology, and Dr. Jon Cacicedo Fernández de Bobadilla, head of the European Society for Radiotherapy and Oncology, presented the awards. Jon Cacicedo Fernández de Bobadilla, head of the Department of Radiation Oncology at Cruces University Hospital, presented the latest innovations in radiation oncology. The awards were then presented in the framework of a special session in which the speakers addressed the great challenge of translational research.
In this third edition, the first prize was awarded to Paola Anna Jablonska for her research on the presence of activated STAT3 in necrosis derived from radiation treatments, which represents a solution to mitigate side effects derived from stereotactic radiosurgery, such as brain necrosis. The second prize was awarded to María José Serrano Fernández for her work on the detection of biomarkers to predict resistance to chemoradiotherapy, such as miRNA-30c, with the aim of optimizing the effectiveness of treatment. Finally, the third prize went to Francisco J. Núñez-Benjumea for his study on the comparison of machine learning approaches to predict radiation toxicities. Dr. Marco Panichi, director of the IOA of Atrys and Sanitas and co-director of the Chair, was in charge of presenting the awards to the winning researchers.
In the words of Dr. Ferrán Guedea, Director of Radiation Oncology at ICO and Director of the UB Atrys Chair, “these awards underline the importance of continuing to promote translational research of excellence in Radiation Oncology. Within the framework of the Chair of the University of Barcelona and Atrys, we will continue to promote the development and dissemination of knowledge, as well as specialized teaching and innovation to advance cancer therapy, with the commitment to make them more effective and personalized”.
The researcher awarded with the first prize, Paola Anna Jablonska, stressed “the essential role played by awards such as this one, which act as a loudspeaker to bring research closer and disseminate it throughout the scientific community. Faced with the challenge of diseases such as cancer, promoting innovative projects, facilitating collaboration between specialists and researchers and encouraging scientific dissemination are essential levers to promote advances in this field”.
The event was closed by Santiago de Torres, CEO of Atrys, who underscored the value of continuing to promote research in the field of radiotherapy to advance cancer treatment: “At Atrys we are specialists in the implementation of single-dose radiotherapy techniques, and we have oncology centers in Spain and Portugal equipped with state-of-the-art machinery to offer a comprehensive, precise, personalized and effective response to cancer patients,” he said. “As a prevention, diagnosis and treatment company, we want to be at the forefront of cancer treatment and it is an honor to be part of projects that recognize and promote innovation in this field, while at the same time boosting research talent so that, together, we can move forward in building a more sustainable and efficient healthcare system.”
Predictive diagnostics and personalization for cancer treatment
The UB Atrys Chair in Personalized Radiotherapy was created with the mission of promoting research in the field of precision radiation oncology, focusing on three main lines of action: the personalization of radiotherapy treatments through studies of radiosensitivity and radiotoxicity, to optimize their effectiveness and minimize side effects; predictive diagnosis prior to high-precision radiotherapy; and the impact of radiotherapy on the immune response against cancer, in order to develop new therapeutic strategies based on immunotherapy.
In this edition, the awarded research articles were:
Paola Anna Jablonska | 1st Prize Chair. Department of Radiation Oncology, Clínica Universidad de Navarra.
Paper: Presence of Activated (Phosphorylated) STAT3 in Radiation Necrosis Following Stereotactic Radiosurgery for Brain Metastases.
The study investigates the role of phosphorylated STAT3 protein (pSTAT3) in brain necrosis caused by stereotactic radiosurgery (SRS) for the treatment of brain metastases. Radiation necrosis (RN) is a late adverse effect of radiotherapy associated with an exaggerated inflammatory response in brain tissue. STAT3 activation plays a key role in the inflammatory response associated with radiation necrosis. This suggests that STAT3 inhibition could be a promising strategy to mitigate symptomatic necrosis in patients with brain metastases treated with stereotactic radiosurgery.
María José Serrano Fernández | 2nd Chair Award. Division of Integral Oncology, Hospital Virgen de las Nieves, Granada.
Work: Baseline extracellular vesicle miRNA-30c and autophagic CTCs predict chemoradiotherapy resistance and outcomes in patients with lung cancer.
This study investigates the role of some non-invasive liquid biopsy markers such as microRNAs (miRNAs) associated with extracellular vesicles and autophagic circulating tumor cells (CTCs), present in blood samples, as predictive biomarkers of resistance to chemoradiotherapy (cCRT) in patients with advanced stage non-small cell lung cancer (NSCLC). This is the first study to demonstrate that extracellular vesicle-associated miRNA-30c inhibits tumor autogenesis and predicts response to chemoradiotherapy. The results suggest that miRNA-30c and autophagic CTCs can be used as biomarkers to stratify patients and potentially guide complementary treatments such as immunotherapy or autogenesis inhibitors.
Francisco J. Núñez-Benjumea | 3rd Chair Award. Innovation and Data Analysis Unit, Institute of Biomedicine of Seville.
Work: Benchmarking machine learning approaches to predict radiation-induced toxicities in lung cancer patients.
This study evaluates the use of Artificial Intelligence approaches using machine learning (ML) to predict radiation-induced toxicities in lung cancer patients undergoing radiotherapy. The aim is to improve clinical decision-making and personalize treatments by predicting common side effects such as esophagitis, cough, dyspnea, and pneumonitis. Data from 875 consecutive lung cancer patients, collected at a Spanish hospital, were analyzed. Three hundred predictive models were developed combining five classifiers. The best models identified new potential predictive variables, such as creatinine and hematocrit levels, which had not previously been related to radiation-induced toxicities.
The company increased its turnover by 5% in the first half of the year compared with the same period in 2023, driven by the growth of all its business areas, especially the Oncology’s area
Adjusted EBITDA reached EUR 25.3 million in the first half of the year, and the adjusted EBITDA margin improved by 368 basis points thanks to optimisation, efficiencies and operating leverage
Atrys is in line with the guidance set for 2024, which envisages a turnover of between 220 and 224 million euros and our EBITDA is between 47 and 49 million euros
Atrys, a global healthtech company providing precision medical prevention, diagnosis and treatment services, pioneer in telemedicine and oncology treatment, has announced its results for the first half of 2024, which reflect the company’s strong performance in all its business areas, and reiterate the guidance for the full year (220-224 million euros in revenues and 47-49 million euros in adjusted EBITDA).
During the first six months of 2024, Atrys reported revenues of €107.4 million, up 5% (6.4% at constant exchange rates) from €102.3 million in the same period of 2023. Adjusted EBITDA improved significantly with a growth of 24.6% compared to the same period in 2023, reaching EUR 25.3 million. Gross Margin grew 2.8% to June to EUR 72.2 million.
In the first semester of 2024, Atrys CAPEX investment decreases to €6 million compared to €6.8 million in H1 2023. Of this, €1.3 million corresponds to expansion CAPEX, specifically the opening of medical oncology centres in Mexico.
Operating Cash Flow increased by 46% and Operating Cash Flow adjusted for non-recurring expenses increased by 43.2% compared to the first six months of FY2023.
Santiago de Torres, CEO of Atrys, said: ‘The company continues to grow organically, improving both revenues and EBITDA, thus meeting the guidance we set for this year. The first half results reflect our leadership position in our main business areas, especially in Medical Oncology. For the remainder of the year, we will continue to strengthen the growth of our core business and introduce new business areas in Chile, which are in demand by both health insurers and the public health system’.
Growth in all its business areas
In the first half of the year, Atrys has consolidated its growth in its main lines of activity in both Spain and Latin America. Specifically, from January to June, the company’s turnover in the Spanish market grew by 4.4% to 81.2 million euros.
In the Latin American market, turnover grew by 8.7% to more than 20 million euros.
By business areas, Atrys’ Oncology division led growth with a turnover 8.7% higher than in the same period last year, especially highlighting the acceleration of the ramp-up of the medical oncology division in Mexico, whose revenues increased from 0.6 million euros in the first half of 2023 to 2.7 million euros in the current financial year.
In the Prevention’s segment, the company recorded a 5.1% increase in turnover compared to 2023, driven by a 7.8% increase in the number of medical check-ups and a 3.1% increase in the average ticket per check-up. It has also been influenced by the improvement in the client renewal rate, which rose from 89% in the first half of 2023 to 92% this year.
To conclude, revenues in the Diagnostics segment grew by 1.8% (6.4% at constant exchange rates), with strong growth in the Laboratory area (Pathology and Genetics), which increased its revenues by 32.8%, due to the good performance of the ramp-up of the Madrid laboratory.
As regards adjusted EBITDA, there was a notable improvement in the margin of all segments, with an increase of 368 b.p. due to the optimisation of efficiencies and the improvement in operating leverage.
Today, Wednesday 31 July, at 10:00h, the Atrys H1 2024 results presentation webcast will take place. Registration through this link.
right to left: Najat Driouech Ben Moussa, Montserrat Vendrell Rius, Dr. Arcadi Navarro Cuartiellas, Cristina Sáez Torres, Santiago de Torres, Manel Balcells i Díaz, Dra. Nina Gramunt Fombuena, Dr. Jordi Camí i Morell, Marcelino Elosua, Cristina Maragall Garrigosa and Ricardo de Bedoya.
Neurodegeneration and Alzheimer’s is the new book that forms part of the first Spanish-language collection specialising in technological innovation in health, medicine and medical care promoted by LID Editorial, directed by Santiago de Torres
The authors, Dr. Arcadi Navarro Cuartiellas and Dr. Nina Gramunt Fombuena, explore the scientific and research advances for its prevention and treatment
The meeting took place yesterday at the Barcelona Biomedical Research Park (PRBB) and was attended by Manel Balcells, Minister of Health of the Generalitat de Catalunya
LID Editorial, the Pasqual Maragall Foundation, Atrys, Sanitas and PRBB have presented the fourth title of Health Tech, the first Spanish-language collection specialising in technological innovation in health, medicine and medical care directed by Santiago de Torres and promoted by LID Editorial, with the support of Atrys and Sanitas.
With the title Neurodegeneration and Alzheimer’s, in this fourth volume, Dr. Arcadi Navarro Cuartiellas, director of the Pasqual Maragall Foundation, and Dr. Nina Gramunt Fombuena, neuropsychologist expert in training and dissemination of the same entity, delve into the scientific advances that are revolutionising our understanding of neurodegenerative diseases with an important focus on Alzheimer’s. They also analyse how the application of new technologies and big data is transforming research and paving the way towards a better quality of life for those affected. They also analyse how the application of new technologies and big data is transforming research and paving the way towards a better quality of life for those affected.
The meeting, held at the PRBB, was opened by its Director General, Dr. Jordi Camí, who highlighted the great work of the Pasqual Maragall Foundation, to which the authors belong, and their links with the centre. For his part, Marcelino Elosua, founder and Chair of LID Editorial, said that ‘this book will better explain to everyone not only the medical side of neurodegenerative diseases and Alzheimer’s, but also the impact on society and businesses’.
On the other hand, Ricardo de Bedoya, Northeast Territorial Director of Sanitas Hospitales, explained that they immediately joined the Health Tech project ‘from the conviction that the healthcare model is changing and that technologies can improve patient outcomes and experience, as well as the performance of healthcare professionals’.
Faced with the current healthcare crisis caused by the lack of professionals and inaccessibility, ‘there is no definitive solution, but there are partial solutions, and new technologies are a means of tackling it. AI, big data… are technologies that will help us, as long as we put the patient at the centre,’ said Santiago de Torres, executive president of Atrys and director of the collection.
Neurodegeneration and Alzheimer’s is a book that brings together in a simple way rigorous and quality information to eliminate false myths and beliefs about Alzheimer’s, aimed at both those affected and those around them and their carers.
The presentation of the book took place through a round table discussion, moderated by Santiago de Torres, who was accompanied by the authors, Dr. Arcadi Navarro Cuartiellas and Dr. Nina Gramunt Fombuena, and the journalist specialising in science and health, Cristina Sáez.
‘There is a paradigm shift with respect to Alzheimer’s, the focus is no longer on finding a solution to cure it, but rather solutions to prevent it. Today, ‘there is greater knowledge about what it is and a greater concern for prevention,’ said Cristina Sáez.
‘Prevention is the key,’ said Dr Nina Gramunt Fombuena. ‘We know that one in three cases of Alzheimer’s can be prevented by adopting a healthy lifestyle: nutrition, physical activity, rest, cognitive activity… What is good for the heart is good for the brain,’ she said.
For his part, Dr. Arcadi Navarro stressed that ‘thanks to the science we do in organisations such as the Pasqual Maragall Foundation, we are at a crucial moment in the management of Alzheimer’s with the arrival of new drugs and the development of biomarkers that will allow early detection and treatment, which gives hope to those affected and their families’.
The final touch was provided by Manel Balcells, Minister of Health of the Generalitat de Catalunya, stressing that Alzheimer’s is ‘a reality that concerns us and that occupies us’ and that a global vision and integrated actions at a social and health level are necessary to address the needs of those affected and their carers.
The technological transformation of the health sector
The Health Tech’s collection, promoted by LID Editorial with the support of Atrys and Sanitas, now has four titles, aimed at analysing current trends in the field of medicine:
Digital health and new forms of healthcare, by Jaime del Barrio and Julio Jesús Sánchez, addresses how new technologies and innovations are transforming the sector and examines current trends and their areas of application, including value-based care and digital therapies.
Biotechnology. Solutions for the healthcare of future and wellbeing of the planet, by Ana Polanco and Elisa Díaz Martínez, an essential reading that addresses the importance of scientific dissemination and citizen participation to bring biotechnology closer to society and make citizens perceive the benefits of investment in research and development.
Digital health and social networks. Conect to research, prevention, share, care and heal by Julio Mayol addresses the different applications, benefits and challenges that social platforms present in the field of health, ethical and privacy issues, and a synthesis of key findings and recommendations for a responsible use of networks in the field of health.
Each year, this award honours the three best scientific articles published in internationally renowned journals in the field of radiation oncology.
The UB Atrys Chair was created with the firm intention of promoting progress in the field of precision radiation oncology in order to foster research excellence, specialised teaching and the dissemination of knowledge in this field
Atrys Health (ATRY), a global healthtech company that provides prevention, diagnosis and precision medical treatment services, pioneer in telemedicine and oncology treatment, and the University of Barcelona open the application process for participation in the 3rd edition of the Personalised Radiotherapy Research Awards, linked to the UB Atrys Chair created in 2021.
Each year, this award honours the three best scientific articles published in internationally renowned journals in the field of radiation oncology. The aim is to reward excellence and innovation in research, as well as to promote the dissemination of knowledge in this crucial area for the advancement of cancer treatment.
The total amount earmarked for these prizes is 9,000 euros divided into a first prize of 5,000 euros, a second prize of 3,000 euros and a third prize of 1,000 euros.
All applications received will be reviewed by the evaluation committee of the awards, formed by members of the Chair’s management, the presidency of the Spanish Society of Radiation Oncology (SEOR) and the management of the Institute for Research in Radiation Oncology (IRAD). The selected proposal will be notified to the rector, who will issue the resolution to award the prizes, which will be presented at the symposium ‘Towards a more inclusive, interactive and intelligent horizon’ that will take place during the XXII National Congress of the SEOR to be held in Oviedo on 25-27 September 2024.
The UB Atrys Chair was created with the firm purpose of promoting progress in the field of precision radiation oncology, focusing on three main lines of action: promoting research excellence, specialised teaching and the dissemination of knowledge in the field of radiation oncology. The aim is to achieve greater personalisation of radiotherapy treatments, optimising their efficacy and minimising side effects; to carry out predictive diagnoses prior to treatment in order to select the most appropriate treatment for each case; and to understand how radiotherapy can stimulate the immune response against cancer and develop new therapeutic strategies based on immunotherapy.
Interested researchers will find all the information about the awards and will be able to register via this link until 23:00h on 28 June 2024.
The company increased its turnover by 5% in the first half of the year compared to the same period in 2023, driven by growth in all its business areas, specially in the Oncology area
Adjusted EBITDA reached 25.3 million euros in the first half of the year, and the adjusted EBITDA margin on revenues improved by 368 basis points thanks to optimization, efficiencies and operating leverage
Atrys is in line with the guidance set for 2024, which envisages a turnover of between 220 and 224 million euros and an EBITDA of between 47 and 49 million euros
Atrys, a global healthtech company providing precision medical prevention, diagnosis and treatment services and a pioneer in telemedicine and oncology treatment, has announced its results for the first half of 2024, which reflect the company’s strong performance in all business areas, and reiterate the guidance for the full year (220-224 million euros in revenue and 47-49 million euros in adjusted EBITDA).
During the first six months of 2024, Atrys reported revenues of 107.4 million euros, up 5% (6.4% at constant exchange rates) from 102.3 million euros in the same period of 2023. Adjusted EBITDA improved notably with a growth of 24.6% compared to the same period of 2023, reaching EUR 25.2 million.
Gross Margin recorded a growth of 2.8% to June, reaching 72.2 million euros in the first half of 2024.
In the first half of 2024, Atrys’ CAPEX investment decreased to 6 million euros compared to 6.8 million euros in the first quarter of 2023. Of this, €1.3 million corresponds to expansion CAPEX, specifically the opening of medical oncology centres in Mexico.
Operating cash flow increased by 46% and operating cash flow adjusted for non-recurring expenses increased by 43.2% compared to the first six months of FY2023.
Santiago de Torres, Executive President of Atrys said: ‘The company continues to grow organically, improving both revenue and EBITDA, thus meeting the guidance we set for this year. The first half results reflect our leadership position in our main business areas, especially in Medical Oncology. For the remainder of the year, we will continue to strengthen the growth of our core business and introduce new business areas in Chile, which are in demand by both health insurers and the public health system’.
Growth in all business areas
In the first half of the year, Atrys has consolidated its growth in its main lines of activity in both Spain and Latin America. Specifically, from January to June, the company’s turnover in the Spanish market grew by 4.4% to 81.2 million euros.
In the Latin American market, turnover grew by 8.7% to over 20 million euros.
By business area, Atrys’ Oncology division led growth with a turnover 8.7% higher than in the same period last year, being particularly noteworthy the acceleration of the ramp-up of the medical oncology division in Mexico, whose revenues increased from 0.6 million euros in the first half of 2023 to 2.7 million euros in the current financial year.
In the Prevention segment, the company recorded a 5.1% increase in revenues compared to 2023, driven by a 7.8% rise in the number of medical check-ups and a 3.1% increase in the average ticket per check-up. It has also been influenced by the improvement in the client renewal rate, which has risen from 89% in the first half of 2023 to 92% this year.
Lastly, revenues in the Diagnostics segment grew 1.8% (6.4% at constant exchange rates), with strong growth in the Laboratory area (Pathology and Genetics), which increased its revenues by 32.8%, due to the good performance of the ramp-up of the Madrid laboratory.
As regards adjusted EBITDA, there was a notable improvement in the margin of all segments, with an increase of 368 b.p. due to the optimisation of efficiencies and the improvement in operating leverage.
Today, Wednesday 31 July, at 10:00h, the Atrys H1 2024 results presentation webcast will take place. Register through this link.